Denali Therapeutics Inc
DNLI
查看详细走势图
16.510USD
+0.100+0.61%
收盘 12/31, 16:00（美东）报价延迟15分钟
2.42B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.61%
5天
-2.83%
1月
-9.09%
6月
+18.35%
今年开始到现在
-18.99%
1年
-18.99%
查看详细走势图
TradingKey Denali Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-31操作建议
Denali Therapeutics Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名77/403位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价32.29。中期看，股价处于平稳状态。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Denali Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
18
位分析师
强力买入
评级
32.286
目标均价
+63.97%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Denali Therapeutics Inc亮点
亮点风险
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-5.67，处于3年历史高位
机构加仓
最新机构持股148.33M股，环比增加0.02%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值56.37K
Denali Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Denali Therapeutics Inc简介
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
公司代码DNLI
公司Denali Therapeutics Inc
CEOWatts (Ryan J)
网址https://www.denalitherapeutics.com
常见问题
Denali Therapeutics Inc(DNLI)的当前股价是多少？
Denali Therapeutics Inc(DNLI)的当前股价是 16.510。
Denali Therapeutics Inc的股票代码是什么？
Denali Therapeutics Inc的股票代码是DNLI。
Denali Therapeutics Inc股票的52周最高点是多少？
Denali Therapeutics Inc股票的52周最高点是24.345。
Denali Therapeutics Inc股票的52周最低点是多少？
Denali Therapeutics Inc股票的52周最低点是10.570。
Denali Therapeutics Inc的市值是多少？
Denali Therapeutics Inc的市值是2.42B。
Denali Therapeutics Inc的净利润是多少？
Denali Therapeutics Inc的净利润为-422.77M。
现在Denali Therapeutics Inc(DNLI)的股票是买入、持有还是卖出？
根据分析师评级，Denali Therapeutics Inc(DNLI)的总体评级为--，目标价格为32.286。
Denali Therapeutics Inc(DNLI)股票的每股收益（EPS TTM）是多少
Denali Therapeutics Inc(DNLI)股票的每股收益（EPS TTM）是-2.912。
相关品种
